[go: up one dir, main page]

AU2015202990B2 - Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same - Google Patents

Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same Download PDF

Info

Publication number
AU2015202990B2
AU2015202990B2 AU2015202990A AU2015202990A AU2015202990B2 AU 2015202990 B2 AU2015202990 B2 AU 2015202990B2 AU 2015202990 A AU2015202990 A AU 2015202990A AU 2015202990 A AU2015202990 A AU 2015202990A AU 2015202990 B2 AU2015202990 B2 AU 2015202990B2
Authority
AU
Australia
Prior art keywords
cholesterol
acts
acid
lipoprotein
reagent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2015202990A
Other versions
AU2015202990A1 (en
Inventor
Mitsuhisa Manabe
Mitsuhiro Nakamura
Yuriko Taniguchi
Mitsuaki Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sekisui Medical Co Ltd
Original Assignee
Sekisui Medical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008201734A external-priority patent/AU2008201734B2/en
Priority claimed from AU2012203506A external-priority patent/AU2012203506A1/en
Application filed by Sekisui Medical Co Ltd filed Critical Sekisui Medical Co Ltd
Priority to AU2015202990A priority Critical patent/AU2015202990B2/en
Publication of AU2015202990A1 publication Critical patent/AU2015202990A1/en
Application granted granted Critical
Publication of AU2015202990B2 publication Critical patent/AU2015202990B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A method of a pretreatment of a sample for quantitating cholesterol characterized by, before measuring cholesterol contained in specific lipoproteins, treating the sample containing lipoproteins with an enzyme, the substrate of which is free cholesterol, optionally together with a reaction accelerator; a method for quantitating cholesterol in specific lipoproteins by using the above method; and a kit for quantitating cholesterol in specific lipoproteins to be used in the above quantification method. By using this quantification method, cholesterol in a specific fraction can be convenient ly, accurately arid effi-ciently quantitated fundamentally without resort to polyanion, etc. Thus, this method is appropriately usable in various automatic analyzers.

Description

METHOD OF PRETREATMENT OF SAMPLE FOR QUANTITATING CHOLESTEROL
AND METHOD FOR QUANTITATING CHOLESTEROL IN SPECIFIC LIPOPROTEINS BY USING THE SAME THe present application is a divisional application from Australian patent application 2012203506, which is in turn a divisional application from Australian patent application 2008201734, which is in turn a divisional application from Australian patent application 2005202380, which is in turn a divisional application from Australian patent application 54263/00, the entire disclosures of which are incorporated herein by this reference.
Technical Field
Tms invention relates to a pretreatment method for accurately and efficiently discriminating and quantitating cholesterol, which exists in the specific lipoprotein fraction, by simple procedures while using a small amount of a sampie, and also to a method for measuring cholesterol in the specinc lipoprotein fraction by using the pretreatment method.
Background Art
Lipids such as cholesterol are complexed with apoproteins in blood to form lipoproteins. Depending on differences ,i.n physical properties, lipoproteins are classified into chylomicron, very low density lipoprotein ' V'LDL) , low density lipoprotein (LDL) , high density lipoprotein (HDL), and So on_ Among these lipoproteings, LDL is xnown -o be one or causative substances which induce arteriosclerosis, while HDL is known to show anti-arteriosclerotic activity.
Epidemioiogicdliy, the level of cholesterol in LDL is Known tv, vXh±b±. a positive correlation with the frequency of onset of arteriosclerotic disease while the level of cholesterol in HDL is known to show an inverse correlation with the frequency of onset of arteriosclerotic disease. These days, measurements of cholesterol in LDL or HDL are, therefore, widely conducted for the prevention or diagnosis of ischemic heart diseases.
As methods known for the measurement of cholesterol in LDL or HDL, there are, for example, a method in which LDL or HDL is separated from other lipoproteins by ultracentrifugal separation and is then subjected to a cholesterol measurement; and another method in which subsequent to separation of LDL or HDL from other lipoproteins by electrophoresis, its lipid is stained, and the intensity of a developed color is measured. These methods are however not used practically, because they involve one or more problems in that procedures are intricate and many samples cannot he handled. A method for the measurement of cholesterol in HDL, which is used at present in the field of clinical tests, is the precipitation method in which a precipitation reagent is added to a sample to agglutinate lipoproteins other than HDL, the resulting agglutinate is removed by centrifugation, and cholesterol in isolated supernatant which contains only HDL is then measured. This method is simpler compared with ultracentrifugation or electrophoresis, but due to the inclusion of the procedures to add the precipitation reagent and to perform the separation, requires each sample is a relatively large quantity, and involves a potential problem of causing an analytical error. Furthermore, the entire analysis steps of this method can not he fully automated.
On the other hand, enzymatic methods have been studied for the fractional quantitation of cholesterol in HDL. Known methods include, for example, to conduct an enzymatic reaction in the presence of a bile acid salt and a nonionic surfactant (JP 63-126498 A). This method makes use of the fact that an enzymatic reaction proceeds in proportion to the concentration of cholesterol in LDL in an Initial stage of the reaction and the subsequent reaction velocity is in proportion to the concentration of cholesterol in HDL. A problem however exists in accuracy because the reaction with the cholesterol in HDL and the reaction with cholesterol in other lipoproteins cannot he fully distinguished.
Also included in the known methods is to have lipoproteins other than HDL agglutinated in advance, to cause cholesterol in HDL alone to react enzymatically, and to inactivate the enzyme and at the same time, to redissolve the agglutinate, followed by the measurement of an absorbance (3P 6-242110 A). This method, however, requires at least three procedures to add reagents so that it can be applied only to particular automated analyzers, leading to a problem in a wide applicability, Further, this method is not satisfactory from the standpoint of damages to analytical equipment and disposal of the reagents because of the use of a salt at a high concentration upon redissolution of an agglutinate. A still further method is also known (IP 9-299 A), which comprises causing, in a first reaction, cholesterol oxidase and cholesterol esterase to act upon lipoproteins other than HDL in the presence of a special surfactant and to have cholesterol, which is contained in such other lipoproteins, preferentially reacted, and then measuring cholesterol in HDL while inhibiting any reaction to cholesterol in lipoproteins other than HDL. This method, however, is considerably different from the present invention inter alia in that in the first reaction, the special surfactant, cholesterol oxidase and cholesterol esterase are required at the same time to put, outside the reaction system, both free cholesterol and esterified cholesterol in the lipoproteins other than HDL.
Further, Japanese Patent No, 2,600,065 discloses a method which makes combined use of a precipitation reagent, which is adapted to cause precipitation of lipoproteins other than HDL, and a cholesterol measuring reagent to measure cholesterol (HDL-C) in unprecipitated HDL. This method has practical utility when a modified enzyme is used as enzyme and b-cyclodextrin sulfate is used as a precipitation reagent. This method, however, also involves a problem in accuracy in that turbidity, which occurs as a result of the use of the precipitation reagent, interferes with the measurement system.
Concerning the measurement of HDL-C by a modified enzyme, “SIIBUTSO SHIRYO BUNSEKI (ANALYSIS OF BIOLOGICAL SAMPLES) * , 19(5), 305-320, which is considered to be a published paper on the above-described patented method, discloses that, under the recognition of incapability of measurement of HDL-C in a serum of a hyperlipidemia patient by the modified enzyme due to a positive error {that is, to result in a higher value compared with that obtained by the precipitation method) induced when the modified enzyme is simply introduced into a reaction system, HDL-C was measured by using cyclodextrin sulfate, a polyanion, and magnesium chloride as a precipitation reagent for the avoidance of the positive error.
To reduce the influence of turbidity caused by a precipitation reagent in the above-described patented method, certain techniques are also known, including to make a surfactant exist concurrently (JP 8-116996 A), to use an antibody (JP 9-96637 A), and to employ a sugar compound (JP 7-301636 A), They, however, all require as a premise the inclusion of a reagent which induces formation of an agglutinate, so that it is fundamentally indispensable for them to use a precipitation reagent such as a polyanion.
The present inventors recently found that use of a substance, which acts upon the specific lipoprotein only, makes it possible to accurately quantitate cholesterol in the specific lipoprotein fraction without using a precipitation reagent, and filed patent applications (JP 9-244821). This method has an extremely high correlation with the conventional precipitation method, but compared in measurement values with the precipitation method, this method is recognized to have a similar tendency as the above-described method reported in "SEIBUTSU SH1RY0 BUNSE&I (ANALYSIS OF BIOLOGICAL SAMPLES}88. To obtain data consistent with those obtained by the conventional precipitation method at medical institutions and the like, a polyanion or the like is added.
From the standpoint of the problem of a tarnish or the like on a cuvette and scattering of measurement values, however, it is not desired to add a polyanion or the like and to form a precipitate in a measurement system. Accordingly, it has been strongly desired to eliminate the precipitate from the system. Further, it is also economically unreasonable to use a polyanion or the like for making the resulting data consistent with those obtained by the precipitation method although the polyanion or the like is not needed from the standpoint of the principle of the measurement. Hence, there is also an outstanding desire for its solution.
An object of the present invention is, therefore, to provide a method, which can accurately and efficiently quantitate cholesterol in the specific lipoprotein fraction by simple procedures fundamentally without needing a polyanion or the like and is suitably applicable to various automated analyzers.
Disclosure of the invention
The present inventors proceeded with a thorough investigation for a cause which may be responsible for the above-described problem reported in “SEIBUTSU SHIRYO BUNSRKl (AMALYSIS OF BIOLOGICAL SAMPLES}", that is, the problem that a value of cholesterol in. the specific lipoprotein fraction as quantitated by using a substance which acts only upon a specific lipoprotein such as HDL becomes higher than the corresponding value as determined by the precipitation method; and came to a conclusion that even from non~HDL lipoproteins (LBL, YLDL and the like) the cholesterol of which is not supposed to be measured, a small amount of free cholesterol existing on their surfaces or in the vicinity of their surfaces is liberated to cause a positive error. Based on this finding, it has been found that a cholesterol value obtained by a quantitation method making use of a substance, which acts upon a specific lipoprotein only, becomes consistent with the corresponding value obtained by the precipitation method when the cholesterol value is measured after consuming only free cholesterol in advance under conditions that lipoproteins remain substantially unchanged, leading to the completion of the present invention.
Described specifically, the present invention provides a method for pretreating a sample, which contains various lipoproteins, prior to measuring cholesterol existing in specific one of the lipoproteins in the sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon the sample.
The present invention also provides a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon the sample with the lipoprotein contained therein; and then measuring the cholesterol, which exists in the specific lipoprotein, by using a substance which acts upon the specific lipoprotein only.
The present invention provides a pretreatment agent, comprising an enzyme, which acts upon free cholesterol as a substrate, and substantially no substance which acts upon lipoprotein, when used for a method for pretreating a sample, which contains various lipoproteins, prior to measuring cholesterol existing in specific one of said lipoproteins in said sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon said sample.
The present invention provides a pretreatment agent, comprising an enzyme, which acts upon free cholesterol as a substrate, a reaction accelerator which is selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and substantially no substance which acts upon lipoprotein, when used for a method for pretreating a sample, which contains various lipoproteins, prior to measuring cholesterol existing in specific one of said lipoproteins in sad sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2',6', 2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample .
The present invention provides a kit when used in a method for quantifying cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, including the following reagents: (1) a first reagent comprising cholesterol oxidase and a hydrogen peroxide consuming substance; and (2) a second reagent comprising a substance which acts upon said specific lipoprotein only, cholesterol esterase, and a color developer.
The present invention provides a kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents : (1) a first reagent comprising cholesterol dehydrogenase and a coenzyme; and (2) a second reagent comprising a substance which acts upon said specific lipoprotein only, and cholesterol esterase.
The present invention provides a kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents : (1) a first reagent comprising cholesterol dehydrogenase and a coenzyme; and (2) a second reagent comprising a substance which acts upon said specific lipoprotein only, cholesterol oxidase, cholesterol esterase, peroxidase, and a color developer.
The present invention provides a kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents : (1) a first reagent comprising cholesterol oxidase, cholesterol esterase, and a hydrogen peroxide consuming substance; and (2) a second reagent comprising a substance which acts upon said specific lipoprotein only, and a color developer.
The present invention provides a kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents; (1) a first reagent comprising cholesterol dehydrogenase, a coenzyme, and cholesterol esterase; and (2) a second reagent comprising a substance which acts upon said specific lipoprotein only.
The present invention provides a kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents : (1) a first reagent comprising cholesterol dehydrogenase, a coenzyme, and cholesterol esterase; and (2) a second reagent comprising a substance which acts upon said specific lipoprotein only, cholesterol oxidase, peroxidase, and a color developer.
The present invention provides a kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents : (1) a first reagent comprising cholesterol oxidase and a hydrogen peroxide consuming substance; (2) a second reagent comprising a substance which acts upon said specific lipoprotein only, and (3) a third reagent comprising cholesterol esterase and a color developer.
The present invention provides a kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents : (1) a first reagent comprising cholesterol dehydrogenase and a coenzyme; (2) a second reagent comprising a substance which acts upon said specific lipoprotein only; and (3) a third reagent comprising cholesterol esterase.
The present invention provides a kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents : (1) a first reagent comprising cholesterol dehydrogenase and a coenzyme; (2) a second reagent comprising a substance which acts upon said specific lipoprotein only; and (3) a third reagent comprising cholesterol oxidase, cholesterol esterase, peroxidase, and a color developer.
The present invention provides a kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents : (1) a first reagent comprising cholesterol dehydrogenase, a coenzyme, and a coenzyme reaction product consuming substance; and (2) a second reagent comprising a substance which acts upon said specific lipoprotein only, and cholesterol esterase.
The present invention provides a kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents : (1) a first reagent comprising cholesterol dehydrogenase, a coenzyme and a coenzyme reaction product consuming substance; and (2) a second reagent comprising a substance which acts upon said specific lipoprotein only, cholesterol esterase, and a color developer.
The present invention provides a kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2' , 6' 2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents : (1) a first reagent comprising (a) cholesterol oxidase, (b) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2' 6' 2"-perpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and (c) a hydrogen peroxide consuming substance; and (2) a second reagent comprising a substance which acts upon said specific lipoprotein only, cholesterol esterase, and a color developer.
The present invention provides a kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2',6'2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents : (1) a first reagent comprising (a) cholesterol dehydrogenase, (b) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2',6',2'-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and (c) a coenzyme; and (2) a second reagent comprising a substance which acts upon said specific lipoprotein only, and cholesterol esterase.
The present invention provides a kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2',6'2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents : (1) a first reagent comprising (a) cholesterol oxidase, (b) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, (c) cholesterol esterase, and (d) a hydrogen peroxide consuming substance; and (2) a second reagent comprising a substance, which acts upon said specific lipoprotein only, and a color developer.
The present invention provides a kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2',6'2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents : (1) a first reagent comprising (a) cholesterol dehydrogenase, (b) a coenzyme, (c) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and (d) cholesterol esterase; and (2) a second reagent comprising a substance which acts upon said lipoprotein only.
The present invention provides a kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2’,6'2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents : (1) a first reagent comprising (a) cholesterol dehydrogenase, (b) a coenzyme, (c) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and (d) cholesterol esterase; and (2) a second reagent comprising a substance which acts upon said specific lipoprotein only, cholesterol oxidase, peroxidase, and a color developer.
The present invention provides a kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2' , 6' 2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents : (1) a first reagent comprising (a) cholesterol oxidase, (b) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and (c) a hydrogen peroxide consuming substance; (2) a second reagent comprising a substance which acts upon said specific lipoprotein only; and (3) a third reagent comprising cholesterol esterase and a color developer.
The present invention provides a kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2',6'2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents : (1) a first reagent comprising (a) cholesterol dehydrogenase, (b) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2',6'2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and (c) a coenzyme; (2) a second reagent comprising a substance which acts upon said specific lipoprotein only; and (3) a third reagent comprising cholesterol esterase.
The present invention provides a kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2' , 6' 2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents : (1) a first reagent comprising (a) cholesterol dehydrogenase, (b) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2' 6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and (c) a coenzyme; (2) a second reagent comprising a substance which acts upon said specific lipoprotein only; and (3) a third reagent comprising cholesterol oxidase, cholesterol esterase, peroxidase, and a color developer.
The present invention provides a kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2',6'2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents : (1) a first reagent comprising (a) cholesterol dehydrogenase, (b) a coenzyme, (c) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2,,6,,2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and (d) coenzyme reaction product consuming substance; and (2) a second reagent comprising a substance which acts upon said specific lipoprotein only, and cholesterol esterase.
The present invention provides a kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2', 6'2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents : (1) a first reagent comprising (a) cholesterol dehydrogenase, (b) a coenzyme, (c) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and (d) coenzyme reaction product consuming substance; and (2) a second reagent comprising a substance which acts upon said specific lipoprotein only, cholesterol esterase, and a color developer.
The present invention provides a reaction accelerator comprising an enzyme capable of acting upon free cholesterol as a substrate, which is selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, betamethasone acetate, monensin or mevinolin, when used for a method for pretreating a sample, which contains various lipoproteins, prior to measuring cholesterol existing in specific one of said lipoproteins in sad sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2' , 6' , 2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample or a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2',6'2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only.
Brief Description of the Figures
Fig. 1 is a diagram showing a correlation between the present invention in Example 1 and the precipitation method;
Fig. 2 is a diagram showing a correlation between the present invention in Example 2 and the precipitation method; and
Fig. 3 is a diagram showing effects of a reaction accelerator in Example 5.
Best Modes for Carrying Out the Invention
In the present invention, before measuring cholesterol existing in a specific lipoprotein in a sample, an enzyme which acts upon free cholesterol as a substrate is caused to act, as pretreatment, upon the sample such that the free cholesterol is consumed.
As the enzyme which acts upon free cholesterol as a substrate, any enzyme can be used insofar as it acts upon free cholesterol as a substrate. Illustrative are cholesterol dehydrogenase and cholesterol oxidase. They can be of any origins such as microorganism origins, animal origins or plant origins, and can also b© those prepared by genetic engineering. Further, they can be either modified or unmodified chemically. The enzyme is generally used at 0.001 to 100 U/mL, with 0.1 to 100 U/mL being preferred.
Mo particular limitation is imposed on conditions under which the above-described enzyme, which acts upon free cholesterol as a substrate, is caused to act upon the sample, and conditions recommended for the enzyme can be used. It is however necessary to pay attention so that, during a stage in which the enzyme which acts upon free cholesterol as a substate is caused to act upon the sample, a reaction through which an esterified cholesterol is converted into free cholesterol does not take place. Mamely, it is not important whether or not cholesterol esterase exists. What Is needed is to maintain conditions such that cholesterol esterase is not allowed to act practically.
Along with the enzyme which acts upon free cholesterol as a substrate, a coenzyme can be used as needed. As the coenzyme f nicotinamide adenine dinucleotide or the like is usable. Such coenzymes can be used either singly or in combination. The amount to be used varies depending on the coenzyme. The coenzyme may be used at 0.ΟΘ1 to 100 U/mL, preferably at 0.1 to 100 U/mL, although no particular limitation is imposed thereon.
Concerning the enzyme which acts upon free cholesterol as a substrate and is used in the present invention, no limitation is imposed on its origin as described above. Its concentration and the like can be chosen suitably to achieve desired performance and handling ease. Accordingly, if it is desired to have the pretreatment completed in a predetermined time, for example, it is only necessary to use the enzyme in a greater amount, and if it is conversely desired to save the enzyme, it is only necessary to make the pretreatment time longer.
In the case of a diagnostic reagent for exclusive use in measurements by automated analyzers, however, it is desired to meet both of the requirements at the same time, namely, it is required to complete the pretreatment in a short time by using the enzyme in a small amount. In such a case, concurrent existence of a reaction accelerator selected from the below-described group in the pretreatment, which uses an enzyme which acts upon free cholesterol as a substrate, makes it possible to achieve desired performance with a reduced amount of the enzyme without making the pretreatment time longer.
Reaction accelerators usable for the above purpose can include, for example, flufenamic acid, mefenamic acid, 2,2’,6*,2“-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin andmevinolin, including their salts and metal derivatives (aluminum derivatives and the like) wherever such salts and metal derivatives exist. Among these, flufenamic acid and mefenamic acid are known as non-steroidal anti - inf lammatory drugs, and fusidic acid and monensin are known as antibiotics.
Upon using such a compound, as a reaction accelerator, it is necessary to suitably choose its concentration and the like by taking into consideration its physical properties, pH and ionic strength of the measurement system, and the kinds and concentrations of substances existing together.
The concentration of the reaction accelerator can be experimentally determined in accordance with conditions of a measuring system. In general, however, fiufenamic acid can may be used at about 0.01 to 100 mM; fusidic acid at about 0.01 to 10 raMj mefenamic acid, 2,2’ ,6s,2'®~terpyxidine and betamethasone acetate, each, at about 0.01 to 5 mM; monensin and mevinolin, each, at about 0.01 to 1 mM; and tiglic acid at about 1 to 500 mM.
Use of the above-described reaction accelerator has made it possible to reduce the amount of the enzyme, which acts upon free cholesterol as a substrate, to one severalth or to one several tenth. When the enzyme is used in the same amount, on the other hand, the reaction accelerator can shorten the reaction time.
In the above--described pretreatment by the enzyme which acts upon free cholesterol as a substrate (and also by the reaction accelerator, if needed), it is also possible to nse other enzymes (with exclusion of those giving substantial influence to lipoproteins) and salts, buffers for pH regulation, surfactants (with exclusion of those giving substantial influence to lipoproteins), preservatives, proteins such as albumin, and agents having affinity to specific lipoproteins, such as antibodies, antibiotics, saponins, lectins and polyanions to extents not causing agglutination of the specific lipoprotein, such that the action of the enzyme is adjusted, without impairing the specificity of the measurement -
In the present invention, those containing the following ingredients can, therefore, be used as pretreatraent agents for measuring cholesterol existing in specific lipoproteins in samples. (Essential ingredients)
Enzymes which act upon free cholesterol as a substrate, for example, cholesterol dehydrogenase and cholesterol oxidase <, (Optional ingredients)
Reaction accelerators, for example, flufenamic acid, mefenamic acid, 2,2',68,2*-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin and mevinolin, (Other ingredients) coenzymes such as MM>, other enzymes such as peroxidase, catalase, diaphorase and ascorbate oxidase, acids such as pyruvic acid, salts, buffers for pH regulation, surfactants giving no substantial influence on lipoproteins, preservatives, proteins such as albumin, antibodies, antibiotics, saponins, lectins, polyanions and couplers such as 4-aminoantipyrine, oxidative color developers such as hydrogen donors, e. g., Trinder * s reagent, electron acceptors such as phenazine metbosulfate, and reductive color developers such as nitroblue tetrazolium.
In the present invention, cholesterol which exists in . a specific lipoprotein in a sample is measured after having free cholesterol in lipoproteins consumed by the above-described pretreatment.
Any method can be used for the measurement of the cholesterol existing in the specific lipoprotein in the sample insofar as the method can measure the cholesterol existing in the specific lipoprotein by using a substance which acts upon the specific lipoprotein only.
An illustrative example of the method may comprise providing, as the substance which acts upon the specific lipoprotein, a surfactant selected from polyoxyethylene alkylene phenyl ethers or polyoxyethylene alkylene tribenzylphenyl ethers disclosed in JP 11-56395 A,* adding a cholesterol measuring enzyme reagent in the presence of the substance? and then measuring the amount of cholesterol reacted in a time during which cholesterol in high density lipoprotein out of lipoproteins preferentially reacts with the cholesterol measuring enzyme reagent.
Examples of commercial products of the former surfactants, polyoxyethylene alkylene phenyl ethers, can include “Emulgen Ά-608® (trade name, product of Kao Corporation), while examples of commercial products of the latter surfactants, polyoxyethylene alkylene tribenzylphenyl ethers, can include “Emulgen B66® (trade name, product of Kao Corporation).
As an alternative method, there is a method which makes use of the modified enzymes, which are disclosed on pages 305-320 of * SEIBUTSU SHIRYO BUMSEKI (ANALYSIS OF BIOLOGICAL SAMPLES) , 19( 5), as substances which act only upon specific lipoproteins, respectively. Although &amp; "cyclodextrin sulfate and magnesium chloride are used in the method of this paper to inhibit reactions with lipoprotein fractions other than HDL, the use of the above-described pretreatment method of this invention makes it no longer necessary to use such substances.
Except for the use of the substance which acts upon the specific cholesterol, the method for the measurement of cholesterol existing in the specific lipoprotein can be practiced by using reagents employed in conventional cholesterol-measuring methods. Examples of ingredients which may be contained in reagents to be used can include enzymes such as cholesterol esterase, cholesterol oxidase, cholesterol dehydrogenase, isocitrate dehydrogenase, diaphorase and peroxidase, color developers, coenzymes, electron acceptors, proteins (albumin, etc.), preservatives, surfactants, salts, acids, and buffers for pH regulation.
As surfactants out of the above-described ingredients, both ionic and nonionic surfactants are usable. Illustrative are polyoxyethylene alkyl ethers, polyoxyethylene alkylphenyl ethers, polyoxyethylene-polyoxypropylene condensate, polyoxyethylene alkyl ether sulfates, alkylbenzenesulfonate salts, and bile acid salts. The amount of the surfactant to be used varies depending on the compound. The surfactant may however be used in 0.0001% to 5%, preferably in 0.001% to 5%, although no particular limitation is imposed thereon.
Mo particular limitation is imposed on the buffers. Conventional buffers such as Good's buffer, phosphate buffer, Tris buffer and phthalate buffer are usable. The buffer may be used at 0.005 M to 2 M, preferably Θ.01 M to 1 M, although no particular limitation is imposed thereon.
The method for quantitating cholesterol in a specific lipoprotein fraction by the present invention typically comprises firstly adding a pretreatment agent, which acts upon free cholesterol only, into a measureing sample and causing the pretreatment agent to act upon the sample, and then adding and mixing a cholesterol measuring reagent (hereafter called a 88quantitation reagent88), which contains a substance capable of acting upon the specific lipoprotein and a reagent employed for a conventional cholesterol-measuring method, to measure the amount of cholesterol in the specific lipoprotein fraction.
Specific examples can include, but are not limited to, a method which comprises mixing cholesterol dehydrogenase and a coenzyme (MAD) with a sample and then adding a cholesterol-measuring reagent which comprises cholesterol esterase and cholesterol oxidase; a method which comprises mixing cholesterol dehydrogenase and MAD with a sample and then adding a cholesterol-measuring reagent which comprises cholesterol esterase i a method which comprises mixing a sample and cholesterol oxidase together with peroxidase, 4-amino antipyrine or catalase and then adding a cholesterol-measuring reagent which comprises cholesterol esterase? and a method which comprises mixing a sample and cholesterol oxidase together with peroxidase, 4-aminoantipyrine, etc. and then adding a cholesterol-measuring reagent which comprises cholesterol esterase, cholesterol dehydrogenase and HAD.
Examples of the method for measuring cholesterol in a specific lipoprotein fraction can include a method making combined use of cholesterol esterase and cholesterol oxidase as an enzyme reagent and a method making combined use of cholesterol esterase and cholesterol dehydrogenase, although known enzyme assays are all usable.
In the present invention, the enzyme for use in the first reaction as the pretreatment reaction and the enzyme for use in the measurement of cholesterol as the quantitation method through the second reaction may be either the same or different. Further, the enzyme may be used in an excess amount in the first reaction andmay also he used in the second reaction. In essence, it is only necessary to consume free cholesterol, which exists in a small amount on lipoprotein surfaces, {first reaction/pretreatment reaction) and then to bring the reaction system into a state, in which the enzyme acts only upon the specific lipoprotein to be measured, so that most cholesterol (free cholesterol + esterifxed cholesterol) forming the lipoprotein can be quantitated.
Further, no particular limitation is imposed on the method for finally detecting cholesterol after the addition of such a cholesterol-measuring enzyme reagent. It is possible to use, for example, absorptiometry in which detection is conducted by combining peroxidase with a chromogen or diaphorase or an electron acceptor with a reductive color-developing reagent? or a method in which a coenzyme or hydrogen peroxide is directly detected. The coenzyme may be amplified by a coenzyme cycling system.
To practice the method of the present invention with ease, it is preferred to use a quantitation kit which is suited for measuring cholesterol in the specific lipoprotein.
Although such kits can be readily designed based on the above explanation, their examples will be described next by dividing them into those making use of cholesterol oxidase and those making use of cholesterol dehydrogenase as typical example of enzymes which act upon free cholesterol as a substrate. [Kits making use of cholesterol oxidase] (a) A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents (1) and (2)? (1) a first reagent comprising cholesterol oxidase and a hydrogen peroxide consuming substance (and further comprising a reaction accelerator in some instances); and (2) a second reagent comprising a substance which acts upon the specific lipoprotein only* cholesterol esterase» and a color developer. (b) A quantitation kit for cholesterol in a specific lipoprotein» comprising the following reagents (1) and (2);
Cl) a first reagent comprising cholesterol oxidase, cholesterol esterase* and a hydrogen peroxide consuming substance (and further comprising a reaction accelerator in some instances)? and (2) a second reagent comprising a substance which acts upon the specific lipoprotein only» and a color developer, (c) A quantitation kit for cholesterol in a specific lipoprotein» comprising the following reagents (I), (2) and (3) : (1) a first reagent comprising cholesterol oxidase and a hydrogen peroxide consuming substance (and further comprising a reaction accelerator in some instances)? (2) a second reagent comprising a substance which acts upon the specific lipoprotein only? and C 3) a third reagent comprising cholesterol esterase and a color developer.
In the above-described kits» the terra ’’hydrogen peroxide consuming substance" means a substance which consumes and eliminates hydrogen peroxide produced by the reaction between cholesterol oxidase and cholesterol. Illustrative are catalase» couplers such as 4-aminoantipyrine, and oxidative-reductive color developer agents including hydrogen donors such as Trinder * s reagent.
Among these, a coupler such as 4-aminoantipyrine and a hydrogen donor such as Trinder * s reagent develop a color when reacted, in combination, with hydrogen peroxide, and are usable as the color developer in the above-described reagent (2) or (3). As the reagent (1) for use in the pretreatment step according to the present invention, it is preferred to use only one of a coupler and a hydrogen donor and to have hydrogen peroxide consumed through a non-color developing reaction. Heedless to say, it is also possible to subject hydrogen peroxide to a color-developing reaction and then to make an adjustment to a measured value [this adjustment can he made by subtracting the intensity of a color, which is developed by the reagent {1), from the intensity of a color developed by the reagent C 2) or the reagent {3)3.
[Kits making use of cholesterol dehydrogenase] (d) A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents (1) and (2); (1) a first reagent comprising cholesterol dehydrogenase and a coenzyme (and further comprising a reaction accelerator in some instances)! and (2) a second reagent comprising a substance, which acts upon the specific lipoprotein only, and cholesterol esterase. (e) A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents (1) and {2)t C1} a first reagent comprising cholesterol dehydrogenase and a coenzyme (and further comprising a reaction accelerator in some instances) % and (2) a second reagent comprising a substance which acts upon the specific lipoprotein only, cholesterol oxidase, cholesterol esterase, peroxidase, and a color developer. {£} A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents (1) and (2)? C1) a first reagent comprising cholesterol dehydrogenase, a coenzyme, and cholesterol esterase(and further comprising a reaction accelerator in some instances); and (2) a second reagent comprising a substance which acts upon the specific lipoprotein only. (g) A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents (1) and (2): C1) a first reagent comprising cholesterol dehydrogenase, a coenzyme, and cholesterol esterase(and further comprising a reaction accelerator in some instances}; and C 2) a second reagent comprising a substance which acts upon the specific lipoprotein only, cholesterol oxidase, peroxidase, and a color developer. (h) A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents (1), (2) and C 3} s C1) a first reagent comprising cholesterol dehydrogenase and a coenzyme (and further comprising a reaction accelerator in some instances)? (2) a second reagent comprising a substance which acts upon the specific lipoprotein only; and (3) a third reagent comprising cholesterol esterase. C i) A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents (1), (2) and ( 3) : {1) a first reagent comprising cholesterol dehydrogenase and a coenzyme(and further comprising a reaction accelerator in some instances},* (2) a second reagent comprising a substance which acts upon the specific lipoprotein only? and (3} a third reagent comprising cholesterol oxidase, cholesterol esterase, peroxidase, and a color developer. (j) A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents (1) and (2)s (1) a first reagent comprising cholesterol dehydrogenase, a coenzyme, and a coenzyme reaction product consuming substance (and further comprising a reaction accelerator in some instancesand (2) a second reagent comprising a substance, which acts upon the specific lipoprotein only, and cholesterol esterase. (k) A quantitation kit for cholesterol in a specific lipoprotein, comprising the following reagents (1) and (2)5 {1) a first reagent comprising cholesterol dehydrogenase, a coenzyme, and a coensyme reaction product consuming substance (and further coraprising a reaction accelerator in some instances); and (2) a second reagent comprising a substance which acts upon the specific lipoprotein only, cholesterol esterase, and a color developer.
In the above-described kits making use of cholesterol dehydrogenase, the term "coenzyme reaction product consuming substance* means a substance which converts a reduced coenzyme (for example, MADE), which occurs through the reaction among cholesterol, cholesterol dehydrogenase and a coenzyme (for example, MAD), back into the original coenzyme. Illustrative is a combination of lactate dehydrogenase and pyruvic acid (substrate). In each of the above-describedkits, the reaction product of the coenzyme is produced by the addition of the reagent (1). In each of the kits (d), (f), (h) and (j) out of the above-described kits, light of the same wavelength as a color developed by the addition of the reagent (1) may be measured in the measurement stage without advance consumption of the reaction product. In this case, however, it is necessary to quantitate the cholesterol in the specific lipoprotein by subtracting the intensity of a color, which is developed in the pretreatment stage in which the reagent (1) is added, from the intensity of a color developed by the reagent (2) or the reagent (3). As an alternative, it may also be possible to add beforehand the snbstance, which consumes the reaction product, to the reagent (1) and subsequent to consumption of the reaction product, to add the reagent (2) or the reagent (3) for the development of a color. In this case, addition of a substance, which reduces the action of the substance which consumes the reaction product, to the reagent (2) or the reagent (3) is preferred- In each of the kits (e), Cg), Cl) and (k), on the other hand., it is not absolutely necessary to subtract the intensity of the color, which is developed in the pretreatment stage, from the color intensity measured in the measurement stage, because in the measurement stage, a developed color of a wavelength different from the color developed In the pretreatment stage is measured.
It is to he noted that the application of the above-mentioned reaction accelerators, such as f luf enamic acid, mefenamic acid, 2,2 ' , 6 1,2®-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin andmevinolin, is limited neither to the pretreatraeat method or agent of the present invention nor the quantitation method or kit of the present invention for cholesterol in a specific lipoprotein, said quantitation method or kit making use of the pretreatment method or agent.
If a reaction accelerator such, as fulfenamic acid is allowed to exist concurrently upon conducting a cholesterol guantxtation method making use of an enzyme which acts upon free cholesterol as a substrate, for example, a free cholesterol quantitation method making combined use of cholesterol oxidase, peroxidase, a color developer and the like or a total cholesterol quantitation method making combined use of cholesterol oxidase, cholesterol esterase, peroxidase, a color developer and the like, it is obviously possible to bring about advantageous effects such that the amount of the enzyme to be used, said enzyme being capable of acting upon free cholesterol as a substrate and being cholesterol oxidase in the above-exemplified method, can be reduced and the time of the enzymatic reaction can be shortened.
Further, reference to the disclosure of this specification on the cholesterol quantitation method (for example, selection of a surfactant to limit a target of a specific lipoprotein to be measured) makes it possible to more specifically design a quantitation method as desired.
Industrially Applicability
The present invention has made it possible to efficiently quantitate cholesterol in a specific fraction by simple procedures without using a polyanion or the like, to say nothing of a mechanical pretreatraent such as centrifugation. As the methods of the present invention do not form a precipitate which would otherwise occur by the addition of the polyanion or the like, measuring apparatus (especially, cuvettes) and the like remain free of a tarnish and moreover, measured values also remain free of scattering. The methods according to the present invention are, therefore, superior to the conventional cholesterol measuring methods.
Further, as will be demonstrated in subsequent Examples, measurement values showing a high correlation with those obtained by the conventional precipitation method can be obtained even with respect to samples with high triglyceride levels» Therefore, the methods according to the present Invention are also excellent in that they are applicable to various samples without limitation»
In addition, the use of the reaction accelerator makes it possible to use the enzyme, which acts upon free cholesterol as a substrate, in a smaller amount in the pretreatraent stage. As has been described above, tbe methods according to the present invention permit accurate and specif ic measurements of a variety of samples by simple procedures while using the samples in small quantities. Accordingly, they can he applied to various automated analysers and are also extremely useful in the field of clinical tests.
The present invention will next be described in further detail by the Examples, It should however be borne in mind that the present invention is by no means limited to the Examples. Example 1
With respect to each of 30 serum samples containing lipoproteins, the cholesterol in HDL was quantitated by the below-described method according to the present invention and the precipitation method, and the measurement values were compared. (invention method) 10 mM phosphate buffer (First Reagent? pH 8.5) (300 a L), which contained 0.1 U/mL cholesterol dehydrogenase (product of Aman© Pharmaceutical Co., Ltd.), 2.5 ηϋ MAD and 0.03% 4-aminoantipyrine, was added to each sample (3 H L) (pretreatment). About 5 minutes later, a cholesterol quantitation reagent (Second Reagent) (1O0 Uh) - which was composed of IQOmM MRS buffer (pH6) containing 1% “Emulgen B-66* , 1.3 U/mL cholesterol esterase (product of Asahi Chemical Industry Co., Ltd.), 2 U/mL cholesterol oxidase (product of Asahi Chemical Industry Co., Ltd.), 5 U/mL peroxidase (product of Toyob© Co., Ltd.) and 0.04% disulfobutylmetatoluidine - was added.
Just before the addition of the Second Reagent and upon an elapsed time of five minutes after the addition, the absorbance was measured at 6Θ0 nm. From a difference in absorbance, the concentration of HDL cholesterol in the serum sample was determined (2-point method). As a calibration substance, a control serum sample with a known concentration of HDL cholesterol was used. The above procedures were conducted using “Hitachi 7150 automated analyzer M . (Precipitation method) "HDLC 2 "Daxichi® Precipitant* (product of Baiichi Pure Chemicals Co., Ltd.) (200 ML) was mixed with the sample (200 ML), followed by centrifugation at 3,000 rpm for 10 minutes. The supernatant (50 ML) was collected, followed by the mixing with a cholesterol quantitation reagent (3 mL) composed of 100 rmM MES buffer (pH6.5) containing 1% Triton X-100, 1 U/mL cholesterol esterase, 1 11/mL cholesterol oxidase, 5 U/mL peroxidase, 0.04% dxsulfobutylmetatoluidine and 0.04% 4~arainoant±pyrine. After the resulting mixture was incubated at 37*C for 10 minutes, its absorbance at 600 nm was measured to determine the concentration of the cholesterol in HDL. (Results}
The results are shown in Table 1 and FIG. 1.
Table 1
Sample No Precipitation I Invention "Ί gasmlfe No Precipit^Ion'l Invention _ method (mg/dL) j method (mg/dL).........................p * method (mg/dL) | method (mg/dL) 1__73 | 72 16 ~ 54 _3..............................53.............................................. 52 .....................18.......................60 .............. | .......59 4...............................' 54...............................................................54.............................................19 50 52~~~~~ _ 5__5 7 ..............1 ...................5 8~ 20 58 56 6...............................75.....................................................71_______21 38 j- ~ _7 '..............................."""SI .........................§T.................................; 22 56 55 __§_ 52 1 50 I 23 35 3*7 9 i~.................................................43 .......................... 43.......................................'.......Ί_24________ 29" 31 ” _10_1........................58 1 58 25 63 | 60 .........................11................................................................................59......................... 59 ~Π 26 ~ ^ — ΖΙΙΓΤ'ΪΖ .................................49........................ I ......................51................................................................" "27...................................................................33......................~...................36...................................... 13__44 I..................................46 28 52 51 ~' ................................................................70.....................~ 1.........................65................................................................. 29............................ 65...............“ Γ 63 '................................................ Ϊ5 ...........................35..............................................1 38....................... .................................................30 ..........................47...................................................[ 49
As is readily envisaged from the results» the invention method» despite the omission of a polyanion or the like» showed an extremely good correlation with the conventional . precipitation method.
Example 2
Measurements were conducted by another method of the present invention» which was similar to the invention method conducted in Example 1 except that in the first reagent, cholesterol dehydrogenase» MAD and the phosphate buffer were replaced by 5 U/mL cholesterol oxidase (product of Toyobo Co. * Ltd.)» 5 U/mL peroxidase (product of Toyobo Co., Ltd.) and 100 mM MES buffer (pH 6). The measurement values were compared with those obtained by the precipitation method in Example 1. (Results)
The results are shown in Table 2 and FIG. 2.
Table 2
As is readily envisaged from the results, the invention method, despite the omission of a polyanion or the like, showed an extremely good correlation with the conventional precipitation method.
Example 3
Using the reagents of Example 1 and Example 2, five sernra samples of different triglyceride levels were measured. The measurement values were then compared with those obtained by the precipitation method. The results are shown in Table 3.
Table 3
As is shown in Table 3, measurement values of comparable levels with those obtained by the conventional method were also obtained by the present invention with respect to the samples of the high triglyceride levels.
Example 4
Measurements were conducted in a similar manner as in Example 2 except that in the first reagent,, 5 U/mL cholesterol oxidase was changed to give reagent compositions of the ingredient concentrations and combinations shown below in Table 4. The measurement values were compared with those obtained by the precipitation method and also with those obtained by the invention method (standard test system) of Example 2. Incidentally, as a second reagent, the same reagent as the second reagent employed in Example 1 was used. The results are shown in Table 5. (compositions of testing reagents) Table 4
(Results)
Table 5
When the amount of cholesterol oxidase was reduced to one fifth (the test system A) compared with the standard test system (Example 2), the correlation coefficient slightly declined and the value of intercept slightly increased. When the reaction accelerator was used, however, results substantially comparable with those of the standard test system were obtained even when the amount of cholesterol oxidase was one fifth. It has hence become evident from these results that the use of a reaction accelerator makes it possible to reduce the amount of cholesterol oxidase to he used.
Example 5
Reagents J to L shown below In Table 6 were prepared, which commonly contained 1.25 0/mL peroxidase (product of Toyobo Co., Ltd.), 0.01% 4~am±noantipyr±ne, 0.02% disulfo butyl-m-toluidine and 50 mM iWaCl and were different from each other in the kind and pH of buffer and the concentrations of cholesterol oxidase (product of Toyobo Co., Ltd.) and f ulf enamic acid (product of Sigma Chemical Co.).
Table 6
Reagents J to L (300 nL) were separately added to aliquots (3 til.) of each serum sample. After the resultant mixtures were incubated at 37ti for 5 minutes, their absorbances were measured at 600 nra. The above procedures were conducted using the Hitachi 7150 automated analyser.
Four serum samples were measured with Reagents J to L.
With respect to each of Reagents J to L, relative absorbances were calculated for the individual concentrations of cholesterol oxidase and fulfenamic acid by assuming that the absorbance obtained with a reagent containing 5.0 U/mL cholesterol oxidase and 0 mM fulfenamic acid was 100. (Results}
Results, which had been obtained by averaging the relative absorbances of the four samples, are presented in FIG. 3, in which "COD" stands for cholesterol oxidase.
As it readily appreciated from the results, the relative absorbance increased depending upon the concentration of fulfenamic acid irrespective of the pH. It has, therefore, been confirmed that the use of the reaction accelerator makes it possible to reduce the amount of cholesterol oxidase to be used .
It has also become clear that the reaction accelerator is also usable in a method for the measurement of free cholesterol or total cholesterol, which makes use of an enzyme which acts upon free cholesterol as a substrate.
Throughout the description and claims of this specification, the word "-comprise'" and variations of the word, such as "comprising" and "comprises", is not intended to exclude other additives, components, integers or steps.
The discussion of documents, acts, materials, devices, articles and the like is included in this specification solely for the purpose of providing a context for the present invention. It is not suggested or represented that any or all of these matters formed part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.

Claims (28)

  1. The Claims Defining the Invention are as Follows:
    1. A pretreatment agent, comprising an enzyme, which acts upon free cholesterol as a substrate, and substantially no substance which acts upon lipoprotein, when used for a method for pretreating a sample, which contains various lipoproteins, prior to measuring cholesterol existing in specific one of said lipoproteins in said sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon said sample.
  2. 2. A pretreatment agent, comprising an enzyme, which acts upon free cholesterol as a substrate, a reaction accelerator which is selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and substantially no substance which acts upon lipoprotein, when used for a method for pretreating a sample, which contains various lipoproteins, prior to measuring cholesterol existing in specific one of said lipoproteins in said sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample.
  3. 3. A pretreatment agent according to claim 1 of claim 2, comprising an enzyme, which acts upon free cholesterol as a substrate, and substantially no cholesterol esterase.
  4. 4. A pretreatment agent according to claim 2, comprising an enzyme, which acts upon free cholesterol as a substrate, a reaction accelerator which is selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and substantially no cholesterol esterase.
  5. 5. A pretreatement agent according to any one of claims 1-3, wherein said enzyme is cholesterol dehydrogenase or cholesterol oxidase.
  6. 6. A kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents: (1) first reagent comprising cholesterol oxidase and a hydrogen peroxide consuming substance; and (2) a second reagent comprising a substance which acts upon said specific lipoprotein only, cholesterol esterase, and a color developer.
  7. 7. A kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents: (1) a first reagent comprising cholesterol dehydrogenase and a coenzyme; and (2) a second reagent comprising a substance which acts upon said specific lipoprotein only, and cholesterol esterase.
  8. 8. A kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents: (1) a first reagent comprising cholesterol dehydrogenase and a coenzyme; and (2) a second reagent comprising a substance which acts upon said specific lipoprotein only, cholesterol oxidase, cholesterol esterase, peroxidase, and a color developer.
  9. 9. A kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents: (1) a first reagent comprising cholesterol oxidase, cholesterol esterase, and a hydrogen peroxide consuming substance; and (2) a second reagent comprising a substance which acts upon said specific lipoprotein only, and a color developer.
  10. 10. A kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents; (1) a first reagent comprising cholesterol dehydrogenase, a coenzyme, and cholesterol esterase; and (2) a second reagent comprising a substance which acts upon said specific lipoprotein only.
  11. 11. A kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents: (1) a first reagent comprising cholesterol dehydrogenase, a coenzyme, and cholesterol esterase; and (2) a second reagent comprising a substance which acts upon said specific lipoprotein only, cholesterol oxidase, peroxidase, and a color developer.
  12. 12. A kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents: (1) a first reagent comprising cholesterol oxidase and a hydrogen peroxide consuming substance; (2) a second reagent comprising a substance which acts upon said specific lipoprotein only, and (3) a third reagent comprising cholesterol esterase and a color developer.
  13. 13. A kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents: (1) a first reagent comprising cholesterol dehydrogenase and a coenzyme; (2) a second reagent comprising a substance which acts upon said specific lipoprotein only; and (3) a third reagent comprising cholesterol esterase.
  14. 14. A kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents: (1) a first reagent comprising cholesterol dehydrogenase and a coenzyme; (2) a second reagent comprising a substance which acts upon said specific lipoprotein only; and (3) a third reagent comprising cholesterol oxidase, cholesterol esterase, peroxidase, and a color developer.
  15. 15. A kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents: (1) a first reagent comprising cholesterol dehydrogenase, a coenzyme, and a coenzyme reaction product consuming substance; and (2) a second reagent comprising a substance which acts upon said specific lipoprotein only, and cholesterol esterase.
  16. 16. A kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents: (1) a first reagent comprising cholesterol dehydrogenase, a coenzyme and a coenzyme reaction product consuming substance; and (2) a second reagent comprising a substance which acts upon said specific lipoprotein only, cholesterol esterase, and a color developer.
  17. 17. A kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2',6'2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents: (1) a first reagent comprising (a) cholesterol oxidase, (b) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2'6'2"-perpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and (c) a hydrogen peroxide consuming substance; and (2) a second reagent comprising a substance which acts upon said specific lipoprotein only, cholesterol esterase, and a color developer.
  18. 18. A kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2',6'2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents: (1) a first reagent comprising (a) cholesterol dehydrogenase, (b) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2',6',2'-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and (c) a coenzyme; and (2) a second reagent comprising a substance which acts upon said specific lipoprotein only, and cholesterol esterase.
  19. 19. A kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2,,6,2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents: (1) a first reagent comprising (a) cholesterol oxidase, (b) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, (c) cholesterol esterase, and (d) a hydrogen peroxide consuming substance; and (2) a second reagent comprising a substance, which acts upon said specific lipoprotein only, and a color developer.
  20. 20. A kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2',6'2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents: (1) a first reagent comprising (a) cholesterol dehydrogenase, (b) a coenzyme, (c) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and (d) cholesterol esterase; and (2) a second reagent comprising a substance which acts upon said lipoprotein only.
  21. 21. A kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2',6'2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents: (1) a first reagent comprising (a) cholesterol dehydrogenase, (b) a coenzyme, (c) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and (d) cholesterol esterase; and (2) a second reagent comprising a substance which acts upon said specific lipoprotein only, cholesterol oxidase, peroxidase, and a color developer.
  22. 22. A kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2',6'2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents: (1) a first reagent comprising (a) cholesterol oxidase, (b) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and (c) a hydrogen peroxide consuming substance; (2) a second reagent comprising a substance which acts upon said specific lipoprotein only; and (3) a third reagent comprising cholesterol esterase and a color developer.
  23. 23. A kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2',6'2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents: (1) a first reagent comprising (a) cholesterol dehydrogenase, (b) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2',6'2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and (c) a coenzyme; (2) a second reagent comprising a substance which acts upon said specific lipoprotein only; and (3) a third reagent comprising cholesterol esterase.
  24. 24. A kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2',6'2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents: (1) a first reagent comprising (a) cholesterol dehydrogenase, (b) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2' 6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and (c) a coenzyme; (2) a second reagent comprising a substance which acts upon said specific lipoprotein only; and (3) a third reagent comprising cholesterol oxidase, cholesterol esterase, peroxidase, and a color developer.
  25. 25. A kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2',6'2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents: (1) a first reagent comprising (a) cholesterol dehydrogenase, (b) a coenzyme, (c) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and (d) coenzyme reaction product consuming substance; and (2) a second reagent comprising a substance which acts upon said specific lipoprotein only, and cholesterol esterase.
  26. 26. A kit when used in a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2',6'2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only, the kit including the following reagents: (1) a first reagent comprising (a) cholesterol dehydrogenase, (b) a coenzyme, (c) a reaction accelerator selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, and (d) coenzyme reaction product consuming substance; and (2) a second reagent comprising a substance which acts upon said specific lipoprotein only, cholesterol esterase, and a color developer.
  27. 27. A reaction accelerator comprising an enzyme capable of acting upon free cholesterol as a substrate, which is selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, betamethasone acetate, monensin or mevinolin, when used for a method for pretreating a sample, which contains various lipoproteins, prior to measuring cholesterol existing in specific one of said lipoproteins in sad sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2',6',2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample; or when used for a method for quantitating cholesterol existing in a specific lipoprotein in a sample, which comprises causing an enzyme, which acts upon free cholesterol as a substrate, and a reaction accelerator, which is selected from flufenamic acid, mefenamic acid, 2,2',6'2"-terpyridine, tiglic acid, fusidic acid, betamethasone acetate, monensin or mevinolin, to act upon said sample with said lipoprotein contained therein; and then measuring said cholesterol, which exists in said specific lipoprotein, by using a substance which acts upon said specific lipoprotein only.
  28. 28. A reaction accelerator according to claim 27, wherein said enzyme is cholesterol oxidase or cholesterol dehydrogenase .
AU2015202990A 1999-06-21 2015-06-04 Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same Expired AU2015202990B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2015202990A AU2015202990B2 (en) 1999-06-21 2015-06-04 Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP11/174624 1999-06-21
JP2000/26737 2000-02-03
AU2008201734A AU2008201734B2 (en) 1999-06-21 2008-04-16 Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same
AU2012203506A AU2012203506A1 (en) 1999-06-21 2012-06-15 Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same
AU2015202990A AU2015202990B2 (en) 1999-06-21 2015-06-04 Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2012203506A Division AU2012203506A1 (en) 1999-06-21 2012-06-15 Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same

Publications (2)

Publication Number Publication Date
AU2015202990A1 AU2015202990A1 (en) 2015-06-25
AU2015202990B2 true AU2015202990B2 (en) 2017-11-02

Family

ID=53877417

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015202990A Expired AU2015202990B2 (en) 1999-06-21 2015-06-04 Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same

Country Status (1)

Country Link
AU (1) AU2015202990B2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366249A (en) * 1977-12-14 1982-12-28 Boehringer Mannheim Gmbh Storage stable cholesterol oxidase compositions
US5856156A (en) * 1994-10-26 1999-01-05 Boehringer Mannheim Gmbh Microbial cholesterol dehydrogenase, process for its production and use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366249A (en) * 1977-12-14 1982-12-28 Boehringer Mannheim Gmbh Storage stable cholesterol oxidase compositions
US5856156A (en) * 1994-10-26 1999-01-05 Boehringer Mannheim Gmbh Microbial cholesterol dehydrogenase, process for its production and use

Also Published As

Publication number Publication date
AU2015202990A1 (en) 2015-06-25

Similar Documents

Publication Publication Date Title
US20160177371A1 (en) Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same
AU2003204024B2 (en) Methods for quantitating high-density lipoprotein cholesterol
AU719144B2 (en) Method for quantitatively determining LDL cholesterols
US5773304A (en) Method for quantitatively determining cholesterol
JP2600065B2 (en) Determination of cholesterol in high density lipoprotein
EP0878716B1 (en) Measurement of LDL-cholesterol
US8765394B2 (en) Method of quantifying cholesterol in high density lipoprotein and reagent compositions
KR100496753B1 (en) Method for measuring ldl-cholesterol
CA2375210A1 (en) Homogeneous tests for sequentially determining lipoprotein fractions
JP2000325097A (en) Method and reagent for measuring lipoprotein cholesterol
EP1148142B1 (en) Method for quantitating triglyceride in lipoprotein
WO2001094619A1 (en) Method of analyzing components in biological samples
JP4542234B2 (en) Method for pretreatment of sample for determination of cholesterol and method for determination of cholesterol in specific lipoprotein using the same
JP3107492B2 (en) Method for quantification of components in lipoprotein fraction
AU2015202990B2 (en) Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same
AU2012203506A1 (en) Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same
AU2005202380A1 (en) Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same
JPH08103298A (en) High-sensitivity determination of cholesterol and reagent for determination

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired